U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07766317) titled 'Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.' on July 27.
Brief Summary: This is a multicenter, single-arm phase 1/2 clinical trial to evaluate the safety and tolerability of GT201 as a monotherapy or in combination with anti-PD-1 therapy in patients with advanced solid tumors, and to evaluate the efficacy of this therapy.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors Cancer
Intervention:
BIOLOGICAL: GT201
A tumor sample from individual participant is collected through a surgical resection for ex vivo manufacturing of GT201 TIL cell product.
BIOLOGICAL: IL-2 and PD...